Polypeptide as agonist of growth hormone secretagogue receptor and use thereof
A receptor agonist and secretagogue technology, applied in the field of biomedicine, to achieve the effect of novel structure, high agonist activity, and less toxic and side effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1-43
[0172] Embodiment 1-43: Preparation of compound 1-43
[0173] 1. Deprotection: Weigh 0.23g (0.1mmol) of Rink Amide resin and place it in a peptide synthesis reactor, then prepare the deprotection reagent according to the above concentration, add it to the resin, react at room temperature, drain, and again Add piperidine / DMF, react at room temperature, drain and wash with DMF until the test is qualified.
[0174] 2. Condensation reaction: add amino acid and condensing agent to DMF to activate respectively under ice bath conditions, then add activated base to react to obtain activation solution, finally add activation solution to resin, react at room temperature, and use 5% ninhydrin The color reagent makes the resin develop color, and the resin changes color. Drain the solvent and wash it with DMF. After passing the test, drain the solvent, and the condensation reaction is complete at this time.
[0175] 3. Repeat the above deprotection and condensation reactions until the syn...
Embodiment 44
[0187] Embodiment 44: The agonist activity evaluation experiment of polypeptide compound to GHSR-1a (IC 50 )
[0188] The screening of GHSR-1a active compounds is accomplished by recombinantly expressing the receptor. The use of recombinant expression of GHSR-Ia offers several advantages, such as the ability to express the receptor in defined cell systems allowing for easier differentiation of compound responses to GHSR-Ia from responses to other receptors. For example, GHSR-1a can be expressed in cell lines such as HEK293, COS7, and CHO, which usually express GHSR-1a without expression vectors, and the same cell lines without expression vectors can be used as controls.
[0189] The activity of GHSR-1a can be measured using different techniques, for example, by detecting changes in the intracellular conformation of GHSR-1a, changes in G-protein coupling activity, and / or changes in intracellular messengers. Preferably, methods such as the determination of intracellular Ca 2+...
Embodiment 45
[0220] Example 45: Inhibition of Cytochrome P450 Oxidase (CYP450) by Polypeptide Compounds
[0221] The metabolic process of drugs in vivo can be divided into phase I reaction (catabolism) and phase II reaction (anabolism). Phase I reactions include oxidation, reduction, and hydrolysis reactions, mainly catalyzed by cytochrome P450 (CYP450) enzymes. CYP450 enzymes are mainly distributed in the liver, so they are also called liver drug enzymes. Induction and inhibition of CYP450 enzymes have important clinical implications and can lead to clinical drug interactions. Therefore, the inhibition test of CYP450 is often used as a safety index to evaluate the druggability of drugs.
[0222] Cytochrome P450-containing human liver microsomes (0.253 mg / mL protein) were mixed with test compounds (0.05-50 μM), CYPs substrates (10 μM acetaminophen, 5 μM diclofenac, 30 μM mephenytoin, 5 μM dextromethorphan hydrobromide methorphan, 2 μM midazolam), 1.0 mM NADP and incubated at 37° C. for ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com